On December 6, 2019 Beijing Hygea Medical Technology reported that it closed a $28 million Series B funding to develop its minimally invasive cryogenic treatment for cancer (Press release, Hygea Medical Technology, DEC 6, 2019, View Source [SID1234551996]). The round was led by Jianxing Medical Fund under the management of CCB International, with participation from Kunying Capital and Shuncheng Capital. Hygea holds 14 patents for its proprietary HYG KB Cryosurgical System and HYG KBD Sterile Cryosurgical Probes. It is also developing cancer diagnostics. An affiliate of the China Academy of Sciences, Division of Physics and Chemistry, Hygea has been supported by China’s 863 program and other China national and Beijing funds.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!